Clinical trials: Limited Stage Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
Lung cancer is still the leading cause of cancer related-deaths worldwide, with an overall all-stage 5-year survival of approximately 17%. The primary treatment of early stage (I-IIIA) NSCLC is curative surgery.
- Trial name
- IONESCO (NCT03030131)
- Testing
- Durvalumab
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03811002
- Testing
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection
- Where
- 542 sites in United States, Japan
- Volunteers
- 544 people
- Sponsor
- National Cancer Institute (NCI)
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with…
- Trial name
- NCT06869239
- Testing
- Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lymph Node Metastases, Non-small Cell Lung Cancer Stage I
Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1003. Systemic mediastinal lymphadenectomy is deemed indispensable in lung cancer surgery for accurate staging and complete…
- Trial name
- NCT03216551
- Testing
- Intra-operative frozen section
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Fudan University
Lung Cancer (NSCLC)
Postoperative Pulmonary Function Assessment Based on Deep Learning Study
Improvements in low-dose CT screening have led to an increase in early-stage NSCLC diagnoses, with surgical resection-usually lobectomy or segmentectomy-remaining the primary curative option.
- Trial name
- NCT07256457
- Testing
- Segmentectomy, Lobectomy, Bronchoscopic Ablation
- Where
- Hong Kong
- Volunteers
- 192 people
- Sponsor
- Chinese University of Hong Kong
Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I…
- Trial name
- NCT00654030
- Testing
- 1650-G Vaccine
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Edward Hirschowitz
Non-small Cell Lung Cancer, Primary Neoplasm
Synapse 3D With Intravascular Indocyanine Green
With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly.
- Trial name
- NCT03953144
- Testing
- Synapse 3D Lung Modelling, IC-Green (ICG)
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Small Cell Lung Carcinoma
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
This study is an academic-lead, open-label, multicenter, randomized phase II trial for frail limited disease Small Cell Lung Cancer (LD-SCLC) patients.
- Trial name
- DURVALUNG (NCT05617963)
- Testing
- Durvalumab
- Where
- 32 sites in France
- Volunteers
- 100 people
- Sponsor
- UNICANCER
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Non-Small Cell Lung Cancer
Intratumoral Cisplatin for Resectable NSCLC
PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.
- Trial name
- NCT04809103
- Testing
- cis-diamminedichloroplatinum
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Vermont
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
This study uses durvalumab (MEDI 4736), an experimental type of drug made by Astra Zeneca Pharmaceuticals, (limited partnership) LP, which in early studies has shown to possibly reduce the growth of certain types of lung cancer.
- Trial name
- NCT03148327
- Testing
- Durvalumab (MEDI 4736), Radiotherapy
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult…
- Trial name
- NCT06862869
- Testing
- Alectinib
- Where
- 44 sites in China
- Volunteers
- 800 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell transplant or bone marrow transplant may allow the doctor to…
- Trial name
- NCT00011921
- Testing
- filgrastim, carboplatin, epirubicin hydrochloride
- Where
- Switzerland
- Volunteers
- 430 people
- Sponsor
- EBMT Solid Tumors Working Party
Small Cell Lung Cancer Limited Stage
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
Combination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS and PFS in limited disease SCLC patients.
- Trial name
- NCT04602533
- Testing
- Durvalumab, standard of care
- Where
- 15 sites in Germany
- Volunteers
- 105 people
- Sponsor
- Michael Hopp
Non-small Cell Lung Cancer Stage I
Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
Lung cancer is the leading cause of cancer related mortality. At present, surgical treatment is the main choice for early-stage lung cancer. Even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%.
- Trial name
- NCT05097417
- Testing
- traditional Chinese medicine and ablation in the primary tumor sites, ablation
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shanghai 10th People's Hospital
Small Cell Lung Cancer
Serplulimab Combined With CCRT for LS-SCLC.
Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients.
- Trial name
- NCT06295926
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer
Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer
A prospective, two-arm, non-randomized, concurrently controlled, multi-center, open-label, treat and resect study following patients to 1 year.
- Trial name
- INCITE ES (NCT04732520)
- Testing
- Pulsed electric field treatment using the Aliya System
- Where
- 4 sites in Hong Kong, Netherlands and 1 more
- Volunteers
- 47 people
- Sponsor
- Galvanize Therapeutics, Inc.
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC